Comparing the Effects of Memantine and Sodium Valproate in Prevention of Chronic and Episodic Migraine

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Neurology, School of Medicine AND Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Neurology, School of Medicine AND Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Considering high prevalence of treatment failure in migraine and resistance to common drugs and their side effects, trying to find new treatments in chronic and relapsing migraine is important. The aim of this study was comparing the effect on memantine and sodium valpruate in treatment of chronic and episodic migraine headaches.Methods: In a cross-over clinical trial study, 70 patients with chronic or relapsing migraine were selected and randomly divided in two equal groups. The groups were treated using memantine or sodim valruate for 3 months and after 4 weeks of wash-out, the method of treatment was replaced and continued for 3 months. The number of headache attacks, pain intensity, analgesia consumption and duration of headache were compared between the two groups.Findings: Time, intensity and duration of headaches were decreased in both groups significantly; but the number of attacks and duration of headache was not significantly different. The decrease of headache intensity in the memantine groups was significantly higher than the sodium valpruate groups (P = 0.021).Conclusion: Both memantine and sodium valpruate had positive effects for prevention of relapsing migraine attack, headache intensity and duration of headache; but the side effects of memantine in lower and it is a better selection for prevention of migraine headache.

Keywords

References

  1. Chitsaz A, Ghorbani A, Hoseinzadeh H, Nazari F, Norouzi R, Tajic S. Comparison of botulinum toxin type-A and divalproex sodium for prevention of chronic and episodic migraine. Neurology Asia 2012; 17(2): 127-32.
  2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41(7): 646-57.
  3. Hung CI, Liu CY, Yang CH, Wang SJ. The Impacts of Migraine among Outpatients with Major Depressive Disorder at a Two-Year Follow-Up. PLoS One 2015; 10(5): e0128087.
  4. Krymchantowski A, Jevoux C. Memantine in the preventive treatment for migraine and refractory migraine. Headache 2009; 49(3): 481-2.
  5. Mazaheri S, Poorolajal J, Hosseinzadeh A, Fazlian MM. Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial. PLoS One 2015; 10(3): e0120229.
  6. Huang L, Bocek M, Jordan JK, Sheehan AH. Memantine for the prevention of primary headache disorders. Ann Pharmacother 2014; 48(11): 1507-11.
  7. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26(6): 742-6.
  8. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997; 17(2): 73-80.
  9. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987; 44(5): 486-9.
  10. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55(6): 754-62.
  11. Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation 2005; 112(15): 2301-6.
  12. Saper JR, Lake AE, III, Hamel RL, Lutz TE, Branca B, Sims DB, et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology 2004; 62(10): 1687-94.
  13. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16(4): 257-63.
  14. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17(10): 1236-48.
  15. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004; 1(1): 101-10.
  16. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33(7): 1834-9.
  17. Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 2007; 164(12 Suppl): 5-56.
  18. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348(14): 1333-41.
  19. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17(6): 297-305.
  20. Charles A, Flippen C, Romero RM, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 2007; 8(4): 248-50.
  21. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008; 48(9): 1337-42.
  22. Andersen GO, Ritland S. Life threatening intoxication with sodium valproate. J Toxicol Clin Toxicol 1995; 33(3): 279-84.
  23. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12(2): 81-4.
Journal of Isfahan Medical School
Volume 33, Issue 343 - Serial Number 343
May and June 2015
Pages 1157-1167

Files

History

  • Receive Date: 06 May 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics